Cardax Inc (OTCQB:CDXI), a development stage biopharmaceutical company, has announced its financial results for the first quarter of 2020, it was reported on Friday.
The company reported net losses of USD1,002,868 in the first quarter of 2020 compared to a loss of USD1,135,420 in the year-ago period.
The firm raised USD770,000 through the issuance of convertible notes in the first quarter of 2020. Out of USD770,000, USD150,000 was used to pay off a convertible note due in March 2020, with the balance used for general working capital.
The Company believes that its operations, including revenues and any public or private offerings, may be affected in 2020 by the COVID-19 pandemic, although the extent of the impact is uncertain at this time.
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Ridgetech reports net income of USD10.20m in fiscal year 2025
Genomma Lab Internacional announces Q2 2025 results
Sanofi finalizes acquisition of Blueprint Medicines to expand rare disease and immunology portfolio
CVS Health declares quarterly dividend USD0.665 per share
Lilly declares dividend of USD1.50 for Q3
Bavarian Nordic sells US Priority Review Voucher for USD160m
Bavarian Nordic sells US Priority Review Voucher for USD160m
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea